Suppr超能文献

贝母素甲和石耳黄素 A 联合对神经胶质瘤干细胞的协同抗癌作用。

Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells.

机构信息

Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea.

Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University, Asan 31460, Republic of Korea.

出版信息

Molecules. 2022 Nov 17;27(22):7968. doi: 10.3390/molecules27227968.

Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Relapse is frequent and rapid due to glioblastoma stem-like cells (GSCs) that induce tumor initiation, drug resistance, high cancer invasion, immune evasion, and recurrence. Therefore, suppression of GSCs is a powerful therapeutic approach for GBM treatment. Natural compounds berbamine and arcyriaflavin A (ArcA) are known to possess anticancer activity by targeting calcium/calmodulin-dependent protein kinase II gamma (CaMKIIγ) and cyclin-dependent kinase 4 (CDK4), respectively. In this study, we evaluated the effects of concurrent treatment with both compounds on GSCs. Combined treatment with berbamine and ArcA synergistically inhibited cell viability and tumorsphere formation in U87MG- and C6-drived GSCs. Furthermore, simultaneous administration of both compounds potently inhibited tumor growth in a U87MG GSC-grafted chick embryo chorioallantoic membrane (CAM) model. Notably, the synergistic anticancer effect of berbamine and ArcA on GSC growth is associated with the promotion of reactive oxygen species (ROS)- and calcium-dependent apoptosis via strong activation of the p53-mediated caspase cascade. Moreover, co-treatment with both compounds significantly reduced the expression levels of key GSC markers, including CD133, integrin α6, aldehyde dehydrogenase 1A1 (ALDH1A1), Nanog, Sox2, and Oct4. The combined effect of berbamine and ArcA on GSC growth also resulted in downregulation of cell cycle regulatory proteins, such as cyclins and CDKs, by potent inactivation of the CaMKIIγ-mediated STAT3/AKT/ERK1/2 signaling pathway. In addition, a genetic knockdown study using small interfering RNAs (siRNAs) targeting either CaMKIIγ or CDK4 demonstrated that the synergistic anticancer effect of the two compounds on GSCs resulted from dual inhibition of CaMKIIγ and CDK4. Collectively, our findings suggest that a novel combination therapy involving berbamine and ArcA could effectively eradicate GSCs.

摘要

多形性胶质母细胞瘤(GBM)是最具侵袭性的脑肿瘤。由于胶质母细胞瘤干细胞(GSCs)诱导肿瘤起始、耐药性、高癌症侵袭性、免疫逃避和复发,因此复发频繁且迅速。因此,抑制 GSCs 是治疗 GBM 的一种有效治疗方法。天然化合物小檗胺和 ArcA 分别通过靶向钙/钙调蛋白依赖性蛋白激酶 II 伽马(CaMKIIγ)和细胞周期蛋白依赖性激酶 4(CDK4)被认为具有抗癌活性。在这项研究中,我们评估了同时使用这两种化合物对 GSCs 的影响。联合使用小檗胺和 ArcA 协同抑制 U87MG 和 C6 驱动的 GSCs 的细胞活力和肿瘤球形成。此外,两种化合物的同时给药可有效抑制 U87MG GSC 移植鸡胚绒毛尿囊膜(CAM)模型中的肿瘤生长。值得注意的是,小檗胺和 ArcA 对 GSC 生长的协同抗癌作用与通过强烈激活 p53 介导的半胱氨酸蛋白酶级联反应促进 ROS 和钙依赖性细胞凋亡有关。此外,两种化合物的共同处理可显著降低关键 GSC 标志物的表达水平,包括 CD133、整合素 α6、醛脱氢酶 1A1(ALDH1A1)、Nanog、Sox2 和 Oct4。小檗胺和 ArcA 对 GSC 生长的联合作用还导致细胞周期调节蛋白的表达水平降低,例如通过强烈失活 CaMKIIγ 介导的 STAT3/AKT/ERK1/2 信号通路来抑制细胞周期蛋白和 CDK。此外,使用靶向 CaMKIIγ 或 CDK4 的小干扰 RNA(siRNA)的基因敲低研究表明,两种化合物对 GSCs 的协同抗癌作用源于 CaMKIIγ 和 CDK4 的双重抑制。总之,我们的研究结果表明,涉及小檗胺和 ArcA 的新型联合治疗可能有效根除 GSCs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69df/9699626/414d4c86a6dd/molecules-27-07968-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验